Core Insights - Gilead Sciences is undergoing a transformation to create a more sustainable and diversified portfolio, focusing on growth in HIV and expanding into other therapeutic areas [4][11] - The company has made significant investments in virology, particularly in HIV, and is optimistic about the long-acting treatment market and its potential for growth [5][6] - Gilead's clinical pipeline includes 36 trials in oncology and inflammation, with a focus on innovative therapies and cell therapy advancements [7][9] Group 1: Strategic Focus - The company aims to sustain and grow its HIV business while diversifying into other therapeutic areas [4] - Key investments have been made in virology, particularly with the recent advancements in PrEP, which could reshape the market [5] - Gilead is optimistic about the long-acting treatment market, with various options being explored [6] Group 2: Clinical Pipeline and Development - Gilead currently has 36 clinical stage trials in oncology and inflammation, with a focus on Trodelvy and cell therapies [7][8] - The company is developing a Phase II portfolio in oncology and inflammation, with innovative mechanisms being explored [9][10] - The partnership with Arcellx for multiple myeloma presents a significant opportunity for Gilead [9] Group 3: Financial Performance and Growth - Gilead's base business has shown consistent growth, with an 8% increase two years ago, 7% last year, and over 6% this year [21] - The company achieved a 47% operating margin in the second quarter, reflecting effective cost management and growth strategies [22] - Gilead plans to maintain a strong dividend policy while also exploring opportunities for share repurchases [26] Group 4: Market Expansion and Pricing Strategy - The U.S. PrEP market is estimated to be over $3 billion, with potential growth to $4.5 billion through increased adherence and market penetration [43][44] - Gilead is focused on pricing lenacapavir for PrEP based on its unique market position and efficacy data, rather than comparing it to existing treatments [35] - The company is optimistic about expanding PrEP access globally, leveraging strong clinical data to engage with payers [41][42] Group 5: Oncology Strategy - Gilead's oncology business is now a $3 billion run rate, driven by Trodelvy and cell therapy products [52] - The company is focused on expanding Trodelvy's use in earlier lines of breast cancer and exploring its potential in lung cancer [55][59] - Upcoming data from the Arcellx partnership in multiple myeloma is highly anticipated and could significantly impact Gilead's growth in oncology [63]

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.Rahway, New Jersey-based Merck just flashed a Death Cross, signaling potential trouble ahead. Foster City, California-based Gilead is basking in a Golden Cross, a sign of bullish momentum.Merck: Treading On Thin IceMerck, known for its diverse lineup of drugs and vaccines, is seeing its stock wobble. Despite a decent climb of 8.72% over the past year, recent technical signals are turnin ...

Sundry Photography When looking at the last few weeks, we can make statements about Gilead Sciences Inc. (NASDAQ:GILD), which we could seldom make in the last few years. Gilead Sciences not only outperformed the market, but we also had a streak of nine up days in a row. Looking at the last three months, Gilead Sciences performed great and especially since the beginning of July 2024, Gilead Sciences started to outperform the S&P 500 (SPY). Data by YCharts My last article about Gilead Sciences was publish ...

Ridofranz/iStock via Getty Images My previous article, “Gilead Sciences: Seriously Undervalued At Peak Pessimism,” caused quite a stir in the comments, particularly from those Seeking Alpha readers who remain pessimistic about Gilead Sciences, Inc.'s (NASDAQ:GILD) business prospects. However, that hasn't stopped the company's stock price from rising more than 23% in less than three months. In this article, I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failur ...

Biotech giant Gilead Sciences, Inc. (GILD) has gained 16.8% in the past three months compared with the industry’s growth of 7.6%. The stock has also outperformed the sector and the S&P 500.The stock’s performance was hit by pipeline setbacks earlier in the year. Nonetheless, this month, Gilead reported better-than-expected second-quarter results and raised its annual earnings guidance. Revenues increased 5% from the year-ago quarter’s level due to high HIV, oncology and liver disease drug sales. Earnings al ...

Gilead Sciences, Inc. (GILD) announced that the FDA has granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.The candidate was approved under the brand name Livdelzi.PBC is a rare, chronic, autoimmune disease of the bile ducts that currently has no cure.PBC affects approximately 130,000 Americans, primarily ...

Gilead Sciences says it uncovered a dangerous drug-counterfeiting operation in which its HIV medications were tampered with and improperly resold before reaching patients.The scheme, allegedly run out of two New York City pharmacies, identified Peter Khaim, a twice-convicted medical fraudster, as the mastermind, according to court documents unsealed this month. The company described Khaim as one of the most brazen and largest manufacturers and sellers of counterfeit Gilead medications in the country.Gilead ...

On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion.Adjusted EPS was $2.01, up from $1.34 a year ago, beating the consensus of $1.60, primarily driven by lower operating expenses and higher revenues.Also Read: Gilead’s $42.5K Priced HIV Drug Could Be ...

Gilead Sciences cites strong growth in its HIV and oncology portfolios during Q2 2024.Key PointsRevenue of $7.0 billion, up 6% excluding Veklury.Non-GAAP diluted EPS of $2.01.Management maintained full-year guidance for product sales.Gilead Sciences (GILD -3.23%), the biopharmaceutical giant known for its HIV, liver disease, and oncology treatments, announced its second quarter 2024 earnings on Aug. 8. The company reported revenue of $7.0 billion, reflecting a solid performance, particularly in its core HIV ...

Gilead Sciences, Inc. (GILD) reported better-than-expected results in the second quarter and raised its annual earnings guidance.Adjusted earnings per share (EPS) of $2.01 comfortably beat the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company reported adjusted earnings of $1.34 per share.The year-over-year increase was driven by higher revenues and lower operating expenses.Total revenues of $6.9 billion beat the Zacks Consensus Estimate of $6.6, primarily due to high HIV, oncology and ...